Research
Hormonal
GLP-1 receptor agonists have shown early evidence of cardiovascular benefits in obese patients.
GLP-1 RAs may also be beneficial for cardiovascular health in obese patients.
StrongSupportsmedium confidence
In addition to their role in weight loss, these drugs have shown promising early evidence of cardiovascular benefits in obese patients.
Why this rating
The claim is based on early evidence discussed in the review.
Source
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
Fatima Ali Raza et al. · Medicine · 2024
DOI 10.1097/md.0000000000040364
reviewCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1 RAs) have shown promising potential in promoting weight loss and preventing diseases associated with obesity.Strong
- Semaglutide and liraglutide have been approved as weight loss medications due to their effectiveness in promoting significant and sustained weight loss.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →